Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer taps WuXi for new contract studies

This article was originally published in Scrip

Executive Summary

WuXi PharmaTech has struck a new three-year contract with Pfizerto conduct in vitro absorption, distribution, metabolism and excretion (ADME) studies. The firms will develop ADME assays to screen and optimise new drug compounds synthesised for Pfizer by WuXi. The Chinese contract research firm already conducts a variety of work for Pfizer, including in the synthetic and medicinal chemistry areas.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel